Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05031520 · ClinicalTrials.gov registry record
PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 32
- Enrollment target
NCT05031520 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 32 participants.
The verdict
NCT05031520 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 32 participants
- Enrollment target
Study Summary
Among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Myocardial infarction (MI) with non-obstructive coronary artery disease (MINOCA) accounts for 5-20% of patients with MI and preferentially affects women. MINOCA pathogenesis is varied and may include atherosclerotic plaque rupture, plaque erosion with thrombosis, vasospasm, embolization, dissection or a combination of mechanisms. Other patients may have clinically unrecognized myocarditis, or takotsubo syndrome masquerading as MI. Among patients referred for coronary angiography for the evaluation of stable ischemic heart disease, non-obstructive CAD is present in up to \~30% of men and \~60% of women. Stable ischemia with non-obstructive coronary arteries (INOCA) may be due to coronary microvascular dysfunction in up to 40% of these patients. Our understanding of mechanisms of MINOCA and INOCA remain incomplete. Coronary inflammation has been hypothesized as a potential mechanism contributing to coronary spasm in MINOCA and microvascular disease in INOCA.
Interventions
- DRUG Metoprolol
- DRUG Nitroglycerin
- DRUG Isovue
- PROCEDURE Coronary computed tomography angiography (CCTA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05031520
The ClinicalTrials.gov registry entry for NCT05031520 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metoprolol is the first listed.
NCT05031520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05031520 about?
NCT05031520 is a clinical study titled "PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease". Among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Myocardial infarction (MI) with non-obstructive coronary artery disease (MINOCA) accounts for 5-20% of patients with MI and preferentiall...
What is the current status of trial NCT05031520?
This trial is currently terminated. The enrollment target is 32 participants. The study started on 2021-07-12. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT05031520?
The interventions under investigation include: Metoprolol (DRUG), Nitroglycerin (DRUG), Isovue (DRUG), Coronary computed tomography angiography (CCTA) (PROCEDURE).
Who is sponsoring clinical trial NCT05031520?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.